<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CINACALCET.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXTROMETHORPHAN" rxcui="3289">
<ATC code="N07XX59" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large increase of the plasma concentrations of dextromethorphan with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CINACALCET.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of flecanaide with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the flecainide during the treatment with cinacalcet.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CINACALCET.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CINACALCET.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with cinacalcet.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CINACALCET.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of propafenone with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of the propafenone during the treatment with cinacalcet.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>127-CINACALCET.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the cinacalcet and after it is stopped. </COMMENT>
</INTERACTION>
</INTERACTIONS>
